Tenaya Therapeutics Stockholders Approve Expanded Equity Incentive Plan, Increasing Potential Dilution

summarizeSummary

Tenaya Therapeutics stockholders approved an amended equity incentive plan, immediately increasing shares available for issuance by 3% and removing the annual cap on future share reserve increases, signaling significant potential dilution.

check_boxKey Events · Financing and Capital Events · TNYA

• Equity Incentive Plan Approved

  Stockholders approved the Amended and Restated 2021 Equity Incentive Plan, finalizing a proposal previously disclosed on April 16, 2026.

• Immediate Share Increase

  The plan includes a one-time increase of 6,509,966 shares, representing approximately 3% of the company's outstanding shares, reserved for future issuance.

• Evergreen Provision Modified

  The annual "evergreen" provision for share reserve increases will now maintain a 4% of outstanding shares increase without the previous 4 million share annual limit, allowing for potentially larger future increases.

• Director Elections and Auditor Ratification

  Stockholders also approved the routine election of three Class II directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis · TNYA · Life Sciences

Stockholders approved an amended equity incentive plan, which includes an immediate 3% increase in shares reserved for issuance (6.5 million shares) and removes the annual 4 million share cap on the "evergreen" provision. This change means future annual increases to the share reserve will be a full 4% of outstanding shares, potentially leading to greater dilution over time compared to the previous capped structure. While common for employee incentives in biotech, this represents a substantial increase in potential share count.